Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444874 | 0.84 | MEN1 (0.46) | MEN1KMT2ANQO2NPC1RAB9A | |
| SCHEMBL2359585 | 0.79 | CLK1 (0.37) | — | |
| SCHEMBL23867 | 0.77 | TSHR (0.46) | TSHRNOS3NOS2CYP2A6 | |
| SCHEMBL29230355 | 0.75 | MEN1 (0.52) | MEN1KMT2ANQO2TP53CYP3A4 | |
| SCHEMBL14482014 | 0.75 | MEN1 (0.52) | MEN1KMT2ANQO2TP53CYP3A4 | |
| SCHEMBL444814 | 0.75 | KMT2A (0.46) | MEN1KMT2ANQO2NPC1RAB9A | |
| SCHEMBL444569 | 0.75 | KMT2A (0.46) | MEN1KMT2ANQO2NPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL793717 | 0.73 | MEN1 (0.50) | MEN1KMT2ANQO2TP53CYP3A4 | |
| SCHEMBL8328664 | 0.73 | ADCY6 (0.44) | MEN1KMT2AMAPTKDM4ECYP2C9 | |
| SCHEMBL11223077 | 0.71 | NOS3 (0.50) | KDM4ETSHRNOS3NOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242471-B1 | SUBSTITUTED GROUP 4 METAL COMPLEXES, CATALYSTS AND OLEFIN POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-29 | — | — | EP | claimed |
| EP-1501843-A1 | ALKARYL-SUBSTITUTED GROUP 4 METAL COMPLEXES, CATALYSTS AND OLEFIN POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003091265-A1 | ALKARYL-SUBSTITUTED GROUP 4 METAL COMPLEXES, CATALYSTS AND OLEFIN POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-11-06 | — | — | WO | claimed |
| US-6515155-B1 | Group 4 metal complexes of the constrained geometry type, catalysts derived therefrom and polymerization processes using the same, characterized by a nitrogen containing aliphatic or cycloaliphatic moiety that is substituted with one or more | DOW GLOBAL TECHNOLOGIES INC. | 2003-02-04 | — | — | US | claimed |
| US-20030004286-A1 | Alkaryl-substituted Group 4 metal complexes, catalysts and olefin polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2003-01-02 | — | — | US | claimed |
| US-20020165329-A1 | Heat-resistant group 4 metal metallecenes having a nitrogen with aliphatic or cycloaliphatic moiety substituted with aryl group(s)and a silane bridge; high-molecular weight ethylene-alpha olefin copolymers; high concentration of comonomer | KLOSIN JERZY (US) | 2002-11-07 | — | — | US | claimed |
| EP-1253158-A1 | Substituted group 4 metal complexes, catalysts and olefin polymerization process | DOW GLOBAL TECHNOLOGIES INC. (US) | 2002-10-30 | — | — | EP | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2001058933-A2 | SELECTIVE N-ACYLATION OF A82846 GLYCOPEPTIDE ANALOGS | ELI LILLY AND COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001010799-A1 | METHODS FOR PREPARING N-[(ALIPHATIC OR AROMATIC)CARBONYL)]-2-AMINOACETAMIDE COMPOUNDS AND FOR CYCLIZING SUCH COMPOUNDS | AVENTIS PHARMACEUTICAL PRODUCTS INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-1051397-A1 | METHOD FOR PREPARING AN N- (ALIPHATIC OR AROMATIC)CARBONYL]-2-AMINOACETAMIDE COMPOUND AND A CYCLYZED COMPOUND | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999038844-A1 | METHOD FOR PREPARING AN N-[(ALIPHATIC OR AROMATIC)CARBONYL]-2-AMINOACETAMIDE COMPOUND AND A CYCLYZED COMPOUND | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | MEN1 3086/4885KMT2A 3611/4885NQO2 1468/4885 |
| US-20020165329-A1 | Heat-resistant group 4 metal metallecenes having a nitrogen with aliphatic or cycloaliphatic moiety substituted with aryl group(s)and a silane bridge; high-molecular weight ethylene-alpha olefin copolymers; high concentration of comonomer | B2M, WEE2, WASF2 | MEN1 2455/4885KMT2A 3396/4885NQO2 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.